Makhzoumi Mohamad

Average Profitability
<0.0001%
Insider Buys Quantity
11
Insider Buys Sum
$134.41M
Insider Sells Quantity
5
Insider Sells Sum
$106,978.74

Insider Activity of Makhzoumi Mohamad

The largest purchase of all time was on 2019-05-09 and amounted to 5000000 shares of Trevi Therapeutics, Inc. for $50M.

The largest sale of all time was on 2022-01-31 and amounted to 4164 shares of Robinhood Markets, Inc. for $59,195.

Biography of Makhzoumi Mohamad

No biography is available at this moment.

2023-07-17PurchaseSavara Inc.
SVRA
10 percent owner
333,333
0.2084%
$3.00$999,999+32.17%
2022-12-21SaleArcellx, Inc.
ACLX
director
179
0.0005%
$30.74$5,502+9.86%
2022-05-03SaleRobinhood Markets, Inc.
HOOD
director
1,952
0.0002%
$10.06$19,640-5.45%
2022-05-02SaleRobinhood Markets, Inc.
HOOD
1,952
0.0002%
$10.06$19,640-8.78%
2022-04-11PurchaseTrevi Therapeutics, Inc.
TRVI
2.63M
3.0873%
$1.90$5M-15.26%
2022-01-31SaleRobinhood Markets, Inc.
HOOD
director
4,164
0.0005%
$14.22$59,195-29.75%
2021-10-18PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
1.85M
11.1305%
$1.62$3M+63.35%
2021-06-28PurchaseMonte Rosa Therapeutics, Inc.
GLUE
10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-03-16PurchaseMarker Therapeutics, Inc.
MRKR
10 percent owner
5.71M
9.5207%
$1.75$10M-4.3%
2020-12-04PurchaseRegulus Therapeutics Inc.
RGLS
10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-07-28PurchaseInozyme Pharma, Inc.
INZY
10 percent owner
250,000
1.2168%
$16.00$4M+19.03%
2020-07-14PurchaseNkarta, Inc.
NKTX
10 percent owner
1.33M
2.1488%
$18.00$24M-11.28%
2020-04-03SaleTrevi Therapeutics, Inc.
TRVI
10 percent owner
1,128
0.0062%
$2.66$3,000+19.07%
2019-07-22PurchaseMirum Pharmaceuticals, Inc.
MIRM
10 percent owner
900,000
5.3814%
$15.00$13.5M+5.09%
2019-05-09PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
5M
34.6117%
$10.00$50M-42.9%
2019-05-07PurchaseRegulus Therapeutics Inc.
RGLS
10 percent owner
1.14M
6.1239%
$1.08$1.23M-40%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.